Unum shares ric­o­chet low­er as pre­mier drug slams in­to its sec­ond safe­ty cri­sis, FDA slaps an­oth­er hold on PhI

Unum Ther­a­peu­tics’ ail­ing shares $UM­RX took a crip­pling hit af­ter the mar­ket closed on Tues­day as ex­ec­u­tives re­vealed that the FDA had slapped a clin­i­cal hold on their pre­mier Phase I drug af­ter a pa­tient in the safe­ty co­hort re­cent­ly ex­pe­ri­enced se­ri­ous ad­verse events that in­clud­ed grade 3 neu­ro­tox­i­c­i­ty and cy­tomegalovirus in­fec­tion as well as grade 4 res­pi­ra­to­ry dis­tress.

And this wasn’t the first time Unum’s run in­to the same set of se­vere safe­ty is­sues with this ther­a­py. 

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER